June 24, 2022

Antihistamine use in cancer patients, missed screenings amid COVID-19

February 17, 2022

1 minute read

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Researchers conducted a study to determine whether commonly used drugs influence responses to cancer treatment. They found that antihistamines were associated with better efficacy of immunotherapy.

Specifically, they reported that patients with melanoma or lung cancer who took H1 antihistamines during immunotherapy had significantly improved clinical outcomes, although further research is needed to confirm the findings. This was the biggest story in hematology/oncology last week.

Source: Adobe Stock

Another headline story involved a report from the American Association for Cancer Research detailing the impact the COVID-19 pandemic has had on the cancer community. The report highlighted the prevalence of missed cancer screenings and treatment delays.

Read these stories and many more in hematology/oncology below:

Antihistamines may impact response to immune checkpoint inhibitors for cancer

According to a retrospective study published in cancer cell. Read more.

AACR report: Pandemic led to almost 10 million missed cancer screenings in 7 months

The American Association for Cancer Research has released a first-of-its-kind report detailing the impact of the COVID-19 pandemic on the cancer community, both in patient care and in research practice. Read more.

Immunotherapy Benefits Elderly Cancer Patients, But Closer Monitoring May Be Warranted

According to the results of a retrospective study conducted in JAMA Oncology. Read more.

Septic shock linked to high mortality rates in patients with hematological malignancies

According to the results of the study published in Journal of the National Comprehensive Cancer Network. Read more.

Revised USPSTF guidelines could reduce racial disparity in access to lung cancer screening

According to a study published in JAMA Oncology. Read more.